Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.4200
+0.02105.26%
Volume:60.33K
Turnover:23.88K
Market Cap:8.53M
PE:5.50
High:0.4399
Open:0.4000
Low:0.3769
Close:0.3990
Loading ...

Press Release: QT Imaging Announces Third Quarter 2024 Financial Results

Dow Jones
·
13 Nov 2024

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
13 Nov 2024

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
13 Nov 2024

Coinbase launches COIN50 Index to track digital assets

CoinMarketCap
·
13 Nov 2024

Shell welcomes Dutch Court of Appeal ruling

GlobeNewswire
·
12 Nov 2024

BCE reports third quarter 2024 results

CNW Group
·
07 Nov 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

GlobeNewswire
·
06 Nov 2024

Dr. Reddy’s Q2 & H1FY25 Financial Results

Business Wire
·
05 Nov 2024

NXP Semiconductors Reports Third Quarter 2024 Results

GlobeNewswire
·
05 Nov 2024

DMC Global Reports Third Quarter Financial Results

GlobeNewswire
·
05 Nov 2024

Neo-Concept Launches Exclusive REISS x Les100Ciels Collection

TIPRANKS
·
31 Oct 2024

Unveiling the Next Chapter in the Reiss X Les100ciels Collaboration

THOMSON REUTERS
·
31 Oct 2024

Unveiling the Next Chapter in the REISS x Les100Ciels Collaboration

GlobeNewswire
·
31 Oct 2024

Shell announces commencement of a share buyback programme

GlobeNewswire
·
31 Oct 2024

Press Release: Shell plc Third Quarter 2024 Interim Dividend

Dow Jones
·
31 Oct 2024

Shell plc publishes third quarter 2024 press release

GlobeNewswire
·
31 Oct 2024

Precision Drilling Announces 2024 Third Quarter Unaudited Financial Results

GlobeNewswire
·
30 Oct 2024

QT Imaging Granted Renewal of NIH Sponsored Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy

Business Wire
·
29 Oct 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

GlobeNewswire
·
29 Oct 2024

GlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpoint

TIPRANKS
·
29 Oct 2024